Flex Pharma (FLKS) Getting Somewhat Favorable Press Coverage, Study Finds
Media coverage about Flex Pharma (NASDAQ:FLKS) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Flex Pharma earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.9613172778523 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Flex Pharma (NASDAQ FLKS) opened at $4.38 on Monday. Flex Pharma has a one year low of $2.68 and a one year high of $5.93. The stock has a market cap of $78.36, a price-to-earnings ratio of -2.17 and a beta of 3.54.
Flex Pharma (NASDAQ:FLKS) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.06. Flex Pharma had a negative net margin of 2,655.19% and a negative return on equity of 71.39%. The company had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.47 million. research analysts predict that Flex Pharma will post -2.33 earnings per share for the current year.
About Flex Pharma
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma and related companies with MarketBeat.com's FREE daily email newsletter.